All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F22%3A10436968" target="_blank" >RIV/00669806:_____/22:10436968 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216208:11140/22:10436968

  • Result on the web

    <a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=IvVnaMU-sY" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=IvVnaMU-sY</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1016/j.esmoop.2021.100357" target="_blank" >10.1016/j.esmoop.2021.100357</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma

  • Original language description

    Background: Implementation of adjuvant therapies in non-metastatic melanoma improved treatment outcomes in some patients; however, adjuvant therapy can be associated with significant cost and risk of toxicity. Therefore, there is an unmet need to better identify patients at high risk of recurrence. Patients and methods: We carried out an ultrasensitive droplet digital PCR (ddPCR)-based detection of BRAFV600E-mutated circulating tumor DNA (ctDNA) from blood samples prospectively collected before surgery, 1 hour after surgery, and then serially during follow-up. Results: In 80 patients (stages &lt;=III), BRAFV600E mutations were detected in 47.2% of tissue, in 37.7% of ctDNA samples collected before surgery, and in 25.9% of ctDNA samples collected 1 hour after surgery. Patients with detected ctDNA in blood collected 1 hour after surgery compared to patients without detected ctDNA had higher likelihood of melanoma recurrence (P &lt; 0.001) and shorter median disease-free survival (P = 0.001) and overall survival (P = 0.003). Conclusions: Ultrasensitive ddPCR can detect ctDNA in pre- and post-surgical blood samples from patients with resectable melanoma. Detection of ctDNA in post-surgical samples is associated with inferior treatment outcomes.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30204 - Oncology

Result continuities

  • Project

    <a href="/en/project/LTAUSA19080" target="_blank" >LTAUSA19080: Circulating tumor DNA and micro RNA for detection of minimal residual disease and recurrence of malignant melanoma in early stages</a><br>

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Others

  • Publication year

    2022

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    ESMO Open [online]

  • ISSN

    2059-7029

  • e-ISSN

  • Volume of the periodical

    7

  • Issue of the periodical within the volume

    1

  • Country of publishing house

    GB - UNITED KINGDOM

  • Number of pages

    7

  • Pages from-to

    100357

  • UT code for WoS article

    000819873600026

  • EID of the result in the Scopus database

    2-s2.0-85121374655